Drug Eases Migraine Days for Patients Who Failed Prior Treatments
Eptinezumab (Vyepti) reduced the number of monthly migraine days for people who had two to four previous migraine prevention treatment failures, the phase IIIb DELIVER trial showed. Changes in mean monthly migraine days were -4.8 for eptinezumab 100 mg, -5.3 eptinezumab for 300 mg, and -2.1 for placebo from baseline to weeks 1 to 12, […]